Short answer · Medically reviewed summary · Last updated: 2026-05-08
Primary Sclerosing Cholangitis (PSC) was first described in the medical literature in 1924 by French physician Dr. C.D.
What is the history of Primary Sclerosing Cholangitis?
History of Primary Sclerosing Cholangitis: when and how it was discovered, and the milestones in research since, medically reviewed.
Primary Sclerosing Cholangitis (PSC) was first described in the medical literature in 1924 by French physician Dr. C.D. Delbet, though it remained poorly understood for decades. Today, Primary Sclerosing Cholangitis is recognized as a complex, immune-mediated chronic liver disease characterized by the progressive inflammation and scarring of the bile ducts.
When was Primary Sclerosing Cholangitis first identified?
While Dr. Delbet provided the first clinical description in 1924, it wasn't until the 1960s and 70s, with the advent of endoscopic retrograde cholangiopancreatography (ERCP), that clinicians could visualize the characteristic "beaded" appearance of the bile ducts in patients with Primary Sclerosing Cholangitis. For much of the 20th century, the disease was often misdiagnosed as secondary biliary obstruction, leading to unnecessary surgeries.
How has our understanding of Primary Sclerosing Cholangitis evolved?
Historically, Primary Sclerosing Cholangitis was viewed primarily as a structural disease of the biliary tree. Modern research has shifted this perspective, identifying it as a systemic immune-mediated condition with a strong link to Inflammatory Bowel Disease (IBD). Genetic research has revealed specific HLA (Human Leukocyte Antigen) markers that predispose individuals to the condition, moving us away from the misconception that it was simply a localized infection or mechanical blockage.
What are the major milestones in managing the disease?
Treatment for Primary Sclerosing Cholangitis has evolved from purely surgical approaches to targeted symptom management and liver transplantation. Key milestones include:
- 1980s: The introduction of Ursodiol as a primary therapy to improve bile flow.
- 1990s: The refinement of liver transplantation techniques, making it the definitive life-saving intervention for end-stage Primary Sclerosing Cholangitis.
- Modern Era: The use of specialized medications like Vancomycin and Cholestrim powder to address specific complications and improve patient quality of life.
How has patient advocacy shaped the field?
As awareness of Primary Sclerosing Cholangitis has grown, so has the power of patient-driven data. Today, platforms like DiseaseMaps.org allow 36 community members to share their lived experiences, which helps bridge the gap between clinical data and the reality of navigating symptoms like intense itching, fatigue, and jaundice.
Next steps
- Consult with a board-certified hepatologist to discuss the latest clinical trials regarding bile acid modulators.
- Monitor liver function tests regularly to track the progression of Primary Sclerosing Cholangitis.
- Join the DiseaseMaps.org community to connect with others sharing their journey with this condition.
Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician regarding any medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD)
- Orphanet: Rare Disease Database
- OMIM (Online Mendelian Inheritance in Man)
- PSC Partners Seeking a Cure
